Astellas hunts for pipeline deals; Ex-Merck worker gets three years for insider trading;

@FierceBiotech: 5 experts, 1 voice: Biotech bubble? It's different this time. Editor's corner | Follow @FierceBiotech

@JohnCFierce:  put out a "no comment" after its stock had dropped >50% in 2 days. That kind of zombie strategy is a disaster. | Follow @JohnCFierce

> Japanese pharma Astellas is on the hunt for deals to pad out its pipeline, the company told Reuters, focusing on early-stage assets in search of value. More

> Spanish biotech Minoryx Therapeutics raised €19.4 million ($21.7 million) to support its work on treatments for neurodegenerative disease, adding Roche ($RHHBY) to its investor syndicate. News

> The former Merck ($MRK) employee convicted in an insider trading scheme has been sentenced to more than three years in prison. Item

Medical Device News

@FierceMedDev: Abbott's bioresorbable stent meets primary endpoint, but NEJM editorial raises questions. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. Article | Follow @VarunSaxena2

@EmilyWFierce: Pigeons, other birds, lizards...there's a full menagerie at an Indian API maker's facilities. FiercePharmaManufacturing report | Follow @EmilyWFierce

> BMJ: Bayer's Essure calls for more follow-up surgeries than traditional sterilization. More

> Intelesens gets FDA approval for its Zensor wearable vital signs device. Report

Pharma News

@FiercePharma: Vaccine-derived polio case raises ugly head in Laos. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: Have to wonder if FDA issues with PharMEDium played into investment firm's decision to sell. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: $MYL CFO on lack of other bidders for $PRGO: "The silence is deafening." | Follow @CarlyHFierce

> Can J&J's Invokana reap the benefits of Lilly and BI's new cardiac data? Its CFO thinks so. Article

> J&J says it has plenty of firepower for M&A, buyback or no buyback. News

Biotech Research News

> Gene therapy protects neurons in Parkinson's disease mouse study. More

> A promising MEK inhibitor in mice loses some luster in human trials. Report

> Gene therapy study in dogs demonstrates success in preserving vision. Story

> Preclinical research often hypes cancer drugs. Item

> Penn investigators finger a 'turncoat' molecule's key role in Tykerb resistance. Article

Pharma Marketing News

> Merck KGaA hopes to spiff up its image with new logo, fewer names. Story

> GSK scores a Part D exclusive for slow-starting lung meds Incruse, Anoro. Report

> With latest hires, Klick sees sign of more creative times in pharma marketing. More

> Influential cancer group to add drug-cost data to its treatment advice. Story

> AbbVie's Humira, J&J's Invokana lead September's $231M in pharma TV ad spending. Article

Vaccines News

> MedImmune joins GSK, Vanderbilt U in Human Vaccines Project. Story

> Reports: Chinese firm to spend $315M on Ebola vaccine manufacturing plant. More

> University of Maryland HIV vaccine candidate enters human trials. News

> Immunomic licenses allergy vaccine tech to Astellas for $300M. Report

> Pfizer touts Trumenba immunogenicity when administered with Menactra, Adacel. Story

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i